GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (OTCPK:LBLTF) » Definitions » Cyclically Adjusted PS Ratio

Lattice Biologics (Lattice Biologics) Cyclically Adjusted PS Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Lattice Biologics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lattice Biologics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Lattice Biologics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Cyclically Adjusted PS Ratio Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lattice Biologics's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Lattice Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Cyclically Adjusted PS Ratio falls into.



Lattice Biologics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lattice Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2021 is calculated as:

For example, Lattice Biologics's adjusted Revenue per Share data for the three months ended in Jun. 2021 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2021 (Change)*Current CPI (Jun. 2021)
=0/114.6314*114.6314
=0.000

Current CPI (Jun. 2021) = 114.6314.

Lattice Biologics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201109 0.000 95.727 0.000
201112 0.000 95.213 0.000
201203 0.000 96.783 0.000
201206 0.000 96.819 0.000
201209 0.000 97.633 0.000
201212 0.000 96.871 0.000
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.087 99.792 0.100
201603 0.021 100.470 0.024
201606 0.029 101.688 0.033
201609 0.013 101.861 0.015
201612 0.013 101.863 0.015
201703 0.010 102.862 0.011
201706 0.009 103.349 0.010
201709 0.004 104.136 0.004
201712 0.004 104.011 0.004
201803 0.003 105.290 0.003
201806 0.002 106.317 0.002
201809 0.003 106.507 0.003
201812 0.005 105.998 0.005
201903 0.008 107.251 0.009
201906 0.005 108.070 0.005
201909 0.006 108.329 0.006
201912 0.007 108.420 0.007
202003 0.005 108.902 0.005
202006 0.005 108.767 0.005
202009 0.006 109.815 0.006
202012 0.004 109.897 0.004
202103 0.002 111.754 0.002
202106 0.000 114.631 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lattice Biologics  (OTCPK:LBLTF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lattice Biologics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (Lattice Biologics) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (Lattice Biologics) Headlines

No Headlines